Advancements in BPDCN Treatment: Targeted Therapies and Clinical Trials

In this podcast, experts Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, Nicole LeBoeuf, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, and Shai Shimony, MD, Dana-Farber Cancer Institute, Boston, MA, share insights into the clinical presentation, diagnosis, and treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematological malignancy. Dr Luskin and Dr Shimony provide insights from a hematology standpoint, while Dr LeBoeuf explores the diagnosis and pathogenesis of this rare disease through a dermatology perspective. The discussion covers pathology, patient demographics, the use of tagraxofusp and venetoclax, and the importance of collaboration within multidisciplinary teams.

The post Understanding BPDCN: dermatology and hematology perspectives on presentation, diagnosis, treatment, & multidisciplinary care appeared first on VJHemOnc.